Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.

Axel MuendleinKathrin GeigerChristine HeinzleStella GaengerThomas WinderLuciano SevergniniPatrick ReimannEva Maria BrandtnerAndreas LeihererHeinz DrexelThomas DeckerChristoph NonnenbroichTobias Dechow

Published in: Journal of cancer research and clinical oncology (2023)

Our results emphasize the clinical value of circulating RAS mutations in managing mCRC.

Keyphrases

cell free
metastatic colorectal cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
wild type
circulating tumor